ALLERGY TREATMENT DRUGS MARKET ANALYSIS
Moreover, various mergers, agreements, and acquisitions among key players are expected to drive the growth of allergy treatment drugs market over the forecast period. For instance, in July 2018, Glenmark Specialty S.A., a division of Glenmark Pharmaceuticals Ltd. (Glenmark), entered into an exclusive licensing agreement with Seqirus Pty. Ltd., to commercialize Ryaltris in Australia and New Zealand. Ryaltris is a nasal spray used for the treatment of symptoms associated with seasonal allergic rhinitis. Furthermore, rising product approvals by the regulatory authorities are expected to propel the growth of allergy treatment market. For instance, in December 2019, Glenmark Pharmaceuticals Ltd., announced that Seqirus Pty. Ltd., received marketing approval from the Therapeutic Goods Administration (TGA), Australia.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :